Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy
A phase 3 trial of Nuvastatic™ in colorectal cancer, run by Natureceuticals Sdn Bhd, now recruiting.
Overview
Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy is a phase 3 interventional study registered as NCT07669519 by Natureceuticals Sdn Bhd, with 180 participants planned, started 2025-08-18 and due to reach its primary completion in 2027-03-31. Interventions recorded: Nuvastatic™ and Placebo.
Similar pages
not linked directly; found by shared links- TrialXian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA First-In-Human Trial of pTTL in Advanced Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of Gixam's Performance in a FIT Negative Population
Shares Colorectal cancer and the tag pipeline.
- TrialIsunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Shares Colorectal cancer and the tag pipeline.
- TrialTo Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA Clinical Study of Arfolitixorin in Patients With mCRC
Shares Colorectal cancer and the tag pipeline.